Sunday 18 October 2026
Export ENGN’s income statement to Excel — free account
enGene Therapeutics Inc
ENGN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 18.2%, free cash flow grew 28.1% and total debt rose 42.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.67
0.04
−2.34%
Follow ENGN
enGene Therapeutics Inc (ENGN) P/E ratio
enGene Therapeutics Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| ENGN enGene Therapeutics Inc | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| GNLX Genelux Corporation compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)